Progress of hearing loss in neurofibromatosis type 2: implications for future management

被引:0
|
作者
Georgios Kontorinis
Jaya Nichani
Simon R. Freeman
Scott A. Rutherford
Samantha Mills
Andrew T. King
Deborah Mawman
Sue Huson
Martin O’Driscoll
D. Gareth Evans
Simon K. W. Lloyd
机构
[1] Central Manchester University Hospitals NHS Foundation Trust,University Department of Otolaryngology
[2] Salford Royal NHS Foundation Trust,Department of Neurosurgery
[3] Salford Royal NHS Foundation Trust,Department of Neuroradiology
[4] Central Manchester University Hospitals NHS Foundation Trust,Department of Genetics Medicine
[5] University of Manchester,School of Cancer and Enabling Services
[6] Southern Teaching Hospital,Department of Otolaryngology, Institute of Neurosciences
来源
European Archives of Oto-Rhino-Laryngology | 2015年 / 272卷
关键词
Conservative treatment; Deafness; Neurofibromatosis type 2; Tumour size; Vestibular schwannoma; Watch wait rescan protocol;
D O I
暂无
中图分类号
学科分类号
摘要
The objective of this study was to describe changes in hearing over time in patients with neurofibromatosis type 2 (NF2) treated conservatively. A retrospective case review was conducted in a tertiary referral centre. Pure tone audiometry, speech discrimination scores, serviceable hearing (American Academy of Otolaryngology class A or B) and measurement of vestibular schwannoma (VS) size on magnetic resonance imaging were evaluated in 56 patients (89 ears) with NF2 with at least one conservatively managed VS. Over a mean follow-up period of 7 years (range 0.8–21 years) pure tone average thresholds increased gradually with a mean annual rate of 1.3 dB for the right ear (p = 0.0003) and 2 dB for the left ear (p =  0.0009). Speech discrimination scores dropped with an average annual rate of 1.3 and 0.34 % in the right and left ear, respectively. Patients maintained serviceable hearing for an average of 7.6 years (range 2.7–19.3 years). The average annual VS growth was 0.4 mm without any correlation with hearing loss. There was a correlation between patients’ age and pure tone threshold increase (p < 0.05 for both ears). In this selected population of patients with NF2, hearing threshold increases were very slow. In NF2 patients with indolently behaving tumours, serviceable hearing can be maintained for a significant length of time, making conservative management an attractive option.
引用
收藏
页码:3143 / 3150
页数:7
相关论文
共 50 条
  • [31] Chemopreventative celecoxib fails to prevent schwannoma formation or sensorineural hearing loss in genetically engineered murine model of neurofibromatosis type 2
    Wahle, Benjamin M.
    Hawley, Eric T.
    He, Yongzheng
    Smith, Abbi E.
    Yuan, Jin
    Masters, Andi R.
    Jones, David R.
    Gehlhausen, Jeffrey R.
    Park, Su-Jung
    Conway, Simon J.
    Clapp, D. Wade
    Yates, Charles W.
    ONCOTARGET, 2018, 9 (01) : 718 - 725
  • [32] Internal Auditory Canal Decompression for Hearing Maintenance in Neurofibromatosis Type 2 Patients
    Bernardeschi, Daniele
    Peyre, Matthieu
    Collin, Michael
    Smail, Mustapha
    Sterkers, Olivier
    Kalamarides, Michel
    NEUROSURGERY, 2016, 79 (03) : 370 - 376
  • [33] Surgical management of vestibular schwannomas secondary to type 2 neurofibromatosis
    Roche, PH
    Robitail, S
    Thomassin, JM
    Pellet, W
    Régis, J
    NEUROCHIRURGIE, 2004, 50 (2-3) : 367 - 376
  • [34] Current Concepts in Management of Vestibular Schwannomas in Neurofibromatosis Type 2
    Tysome J.R.
    Axon P.R.
    Donnelly N.P.
    Durie-Gair J.
    Gareth Evans D.
    Ferner R.E.
    Macfarlane R.
    Mannion R.
    Nduka C.
    Morris K.
    Pretorius P.M.
    Rands G.
    Rowe J.
    Taylor A.
    Current Otorhinolaryngology Reports, 2014, 2 (4) : 248 - 255
  • [35] Hearing Loss: Diagnosis and Management
    Lasak, John M.
    Allen, Patrick
    Mcvay, Tim
    Lewis, Douglas
    PRIMARY CARE, 2014, 41 (01): : 19 - +
  • [36] Hearing rehabilitation in neurofibromatosis type 2 patients: Cochlear versus auditory brainstem implantation
    Vincenti, Vincenzo
    Pasanisi, Enrico
    Guida, Maurizio
    Di Trapani, Giuseppe
    Sanna, Mario
    AUDIOLOGY AND NEURO-OTOLOGY, 2008, 13 (04) : 273 - 280
  • [37] Hearing Rehabilitation in Patients With Neurofibromatosis Type 2: The Quebec's Experience With Auditory Implants
    Khneisser, Edwina
    Bussieres, Richard
    Cote, Mathieu
    Philippon, Daniel
    Fradet, Gaetan
    Cote, Martin
    Lessard, Nathalie
    Champagne, Pierre-Olivier
    Trudel, Mathieu
    OTOLOGY & NEUROTOLOGY, 2023, 44 (08) : E621 - E627
  • [38] The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2
    Mikkel Christian Alanin
    Camilla Klausen
    Per Caye-Thomasen
    Carsten Thomsen
    Kaare Fugleholm
    Lars Poulsgaard
    Ulrik Lassen
    Morten Mau-Sorensen
    Kenneth Francis Hofland
    European Archives of Oto-Rhino-Laryngology, 2015, 272 : 3627 - 3633
  • [39] Cochlear implantation in a patient with neurofibromatosis type 1 and profound hearing loss: Evidence to support a cochlear site of lesion
    Poissant, SF
    Megerian, CA
    Hume, D
    OTOLOGY & NEUROTOLOGY, 2003, 24 (05) : 751 - 756
  • [40] The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2
    Alanin, Mikkel Christian
    Klausen, Camilla
    Caye-Thomasen, Per
    Thomsen, Carsten
    Fugleholm, Kaare
    Poulsgaard, Lars
    Lassen, Ulrik
    Mau-Sorensen, Morten
    Hofland, Kenneth Francis
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2015, 272 (12) : 3627 - 3633